Skip to main content
Top
Published in: Annals of Hematology 4/2013

01-04-2013 | Original Article

High expression of the Ets-related gene (ERG) is an independent prognostic marker for relapse-free survival in patients with acute promyelocytic leukemia

Authors: Anna Hecht, Daniel Nowak, Verena Nowak, Benjamin Hanfstein, Andreas Faldum, Thomas Büchner, Karsten Spiekermann, Cristina Sauerland, Eva Lengfelder, Wolf-Karsten Hofmann, Florian Nolte

Published in: Annals of Hematology | Issue 4/2013

Login to get access

Abstract

In acute promyelocytic leukemia (APL), relapse occurs in about 15 % of cases and is a major cause for death. Molecular markers identifying patients at high risk for relapse are not well established. High expression of the transcription factor Ets-related gene (ERG) is associated with inferior overall survival (OS) and disease-free survival in different types of hematologic malignancies. There are no data available about the impact of ERG expression in APL. ERG expression levels were analyzed in bone marrow samples of 86 APL patients at initial diagnosis. High ERG expression was significantly associated with an inferior OS in patients who had reached first complete remission. It was also significantly correlated with inferior relapse-free survival (RFS) and time to relapse (i.e., relapse-free interval, RFI). In multivariate analysis, high ERG expression had an independent negative impact on RFS and RFI. High ERG expression was significantly associated with inferior OS, RFS, and RFI. Moreover, in multivariate analysis, it maintained its value as an independent negative prognostic factor with regard to RFS and RFI. Therefore, ERG expression might serve as a molecular marker for risk stratification in APL and might identify patients who could benefit from intensified treatment regimens.
Literature
1.
go back to reference Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ (1997) Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood 89:376–387PubMed Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ (1997) Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood 89:376–387PubMed
2.
go back to reference Brown D, Kogan S, Lagasse E et al (1997) A PMLRARα transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A 94:2551–2556PubMedCrossRef Brown D, Kogan S, Lagasse E et al (1997) A PMLRARα transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A 94:2551–2556PubMedCrossRef
3.
go back to reference Ades L, Guerci A, Raffoux E et al (2010) Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood 115:1690–1696PubMedCrossRef Ades L, Guerci A, Raffoux E et al (2010) Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood 115:1690–1696PubMedCrossRef
4.
go back to reference Sanz MA, Lo Coco F, Martin G et al (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247–1253PubMed Sanz MA, Lo Coco F, Martin G et al (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247–1253PubMed
5.
go back to reference Lengfelder E, Haferlach C, Saussele S et al (2009) High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia 23:2248–2258PubMedCrossRef Lengfelder E, Haferlach C, Saussele S et al (2009) High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia 23:2248–2258PubMedCrossRef
6.
go back to reference Ichikawa H, Shimizu K, Hayashi Y, Ohki M (1994) An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res 54:2865–2868PubMed Ichikawa H, Shimizu K, Hayashi Y, Ohki M (1994) An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res 54:2865–2868PubMed
7.
go back to reference Welford SM, Hebert SP, Deneen B et al (2001) DNA binding domain-independent pathways are involved in EWS/FLI1-mediated oncogenesis. J Biol Chem 276:41977–41984PubMedCrossRef Welford SM, Hebert SP, Deneen B et al (2001) DNA binding domain-independent pathways are involved in EWS/FLI1-mediated oncogenesis. J Biol Chem 276:41977–41984PubMedCrossRef
8.
go back to reference Kuhnl A, Gokbuget N, Stroux A et al (2010) High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. Blood 115:3737–3744PubMedCrossRef Kuhnl A, Gokbuget N, Stroux A et al (2010) High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. Blood 115:3737–3744PubMedCrossRef
9.
go back to reference Baldus CD, Burmeister T, Martus P et al (2006) High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. J Clin Oncol 24:4714–4720PubMedCrossRef Baldus CD, Burmeister T, Martus P et al (2006) High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. J Clin Oncol 24:4714–4720PubMedCrossRef
10.
go back to reference Marcucci G, Maharry K, Whitman SP et al (2007) High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 25:3337–3343PubMedCrossRef Marcucci G, Maharry K, Whitman SP et al (2007) High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 25:3337–3343PubMedCrossRef
11.
go back to reference Metzeler KH, Dufour A, Benthaus T et al (2009) ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol 27:5031–5038PubMedCrossRef Metzeler KH, Dufour A, Benthaus T et al (2009) ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol 27:5031–5038PubMedCrossRef
12.
go back to reference Lengfelder E, Hanfstein B, Haferlach C et al (2012) Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group. Ann Hematol. doi:10.1007/s00277-012-1597-9 Lengfelder E, Hanfstein B, Haferlach C et al (2012) Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group. Ann Hematol. doi:10.​1007/​s00277-012-1597-9
13.
go back to reference Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45PubMedCrossRef Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45PubMedCrossRef
14.
go back to reference Akagi T, Shih LY, Kato M et al (2009) Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations. Blood 113:1741–1748PubMedCrossRef Akagi T, Shih LY, Kato M et al (2009) Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations. Blood 113:1741–1748PubMedCrossRef
15.
go back to reference Yaghmaie M, Mozdarani H, Alimoghaddam K et al (2012) Characterization of arsenic-induced cytogenetic alterations in acute promyelocytic leukemia cell line, NB4. Med Oncol 29:1209–1216PubMedCrossRef Yaghmaie M, Mozdarani H, Alimoghaddam K et al (2012) Characterization of arsenic-induced cytogenetic alterations in acute promyelocytic leukemia cell line, NB4. Med Oncol 29:1209–1216PubMedCrossRef
16.
go back to reference de la Serna J, Montesinos P, Vellenga E et al (2008) Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 111:3395–3402PubMedCrossRef de la Serna J, Montesinos P, Vellenga E et al (2008) Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 111:3395–3402PubMedCrossRef
17.
go back to reference Lehmann S, Ravn A, Carlsson L et al (2011) Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia 25:1128–1134PubMedCrossRef Lehmann S, Ravn A, Carlsson L et al (2011) Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia 25:1128–1134PubMedCrossRef
18.
go back to reference Damm F, Heuser M, Morgan M et al (2011) Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood 117:4561–4568PubMedCrossRef Damm F, Heuser M, Morgan M et al (2011) Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood 117:4561–4568PubMedCrossRef
19.
go back to reference Baldus CD, Martus P, Burmeister T et al (2007) Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol 25:3739–3745PubMedCrossRef Baldus CD, Martus P, Burmeister T et al (2007) Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol 25:3739–3745PubMedCrossRef
Metadata
Title
High expression of the Ets-related gene (ERG) is an independent prognostic marker for relapse-free survival in patients with acute promyelocytic leukemia
Authors
Anna Hecht
Daniel Nowak
Verena Nowak
Benjamin Hanfstein
Andreas Faldum
Thomas Büchner
Karsten Spiekermann
Cristina Sauerland
Eva Lengfelder
Wolf-Karsten Hofmann
Florian Nolte
Publication date
01-04-2013
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 4/2013
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-012-1648-2

Other articles of this Issue 4/2013

Annals of Hematology 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.